Then, recipients of blood products from the 2 groups of donors were identified and followed until 2012. In addition, the clustering of CLL cases among recipients of blood products from specific donors who did or did not develop CLL was assessed.

The incidence of CLL among donors and recipients was evaluated using a Poisson regression analysis, and the overall comparison was conducted using a chi-square goodness-of-fit test.

Among the blood donors, 796 later developed CLL and 7477 did not. During the follow-up period, CLL developed in 12 patients who received blood from donors with CLL compared with 107 recipients of blood from donors without CLL (incidence rate ratio [IRR], 0.94; 95% CI, 0.52 – 1.71).

RELATED: Large-Scale Genomic Analysis Gives New Insights Into the Chronology, Evolution of CLL

The IRR decreased to 0.46 (95% CI, 0.12 – 1.85) when the exposure period was restricted to less than 10 years before donor CLL diagnosis. Furthermore, there was no evidence of CLL clustering among blood donors and recipients.

“Our analyses provide no evidence that donor MBL/CLL transmission contributes significantly to CLL risk among transfusion recipients,” Hjalgrim stated.


  1. Hjalgrim H, Rostgaard K, Vasan SK, et al. No evidence of transmission of chronic lymphocytic leukemia through blood transfusion [published online ahead of print August 24, 2015]. Blood. doi: 10.1182/blood-2015-03-632844.
  2. Karube K, Scarfo L, Campo E, Ghia P. Monoclonal B cell lymphocytosis and “in situ” lymphoma. Semin Biol. 2014;24:3–14.
  3. Shim YK, Rachel JM, Ghia P, et al. Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood. 2014;123(9):1319–1326.
  4. Adami J, Nyrén O, Bergström R, et al. Blood transfusion and non-Hodgkin lymphoma: lack of association. Ann Int Med. 1997;127(5):365–371.
  5. Blomberg J, Möller T, Olsson H, Anderson H, Jonsson M. Cancer morbidity in blood recipients-results of a cohort study. Eur J Cancer. 1993;29A(15):2101–2105.
  6. Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. JNCI Monogr. 2014;2014(48):41–51.